The findings suggest that tirzepatides substantial enhancements in glucose control and insulin sensitivity contribute to its effectiveness in T2D management

Decreased appetite was also reported in 5% of patients taking semaglutide tablets The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation Ozempic injection: In placebo-controlled trials, discontinuation due to GI adverse reactions was 3.1% and 3.8% for the Ozempic injection 0.5 mg and 1 mg dose, respectively, compared with 0.4% for placebo Semaglutide tablets: 4% and 8% of patients discontinued semaglutide tablets 7 mg and 14 mg, respectively, due to GI adverse reactions, compared with 1% of patients receiving placebo Rates of hypoglycemia in placebo-controlled trials 1-3 Incidence of severe hypoglycemia was 300 mg/g at baseline) were randomized 1:1 to receive Ozempic injection 1 mg (n=1767) or placebo (n=1766) once-weekly, both in addition to standard-of-care treatments, including a maximum tolerated labeled dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent, including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment was contraindicated or not tolerated

Stable performance matters just as much
This can lead to lower calorie intake and, over time, weight loss